"Biological Availability" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.
| Descriptor ID |
D001682
|
| MeSH Number(s) |
G03.787.151 G07.690.725.129
|
| Concept/Terms |
Biological Availability- Biological Availability
- Availability, Biological
- Availabilities, Biological
- Biological Availabilities
- Biologic Availability
- Physiologic Availability
- Availability, Biologic
- Availabilities, Biologic
- Biologic Availabilities
- Bioavailability
- Bioavailabilities
- Availability, Physiologic
- Availabilities, Physiologic
- Physiologic Availabilities
Availability Equivalency- Availability Equivalency
- Availability Equivalencies
- Equivalencies, Availability
- Equivalency, Availability
|
Below are MeSH descriptors whose meaning is more general than "Biological Availability".
Below are MeSH descriptors whose meaning is more specific than "Biological Availability".
This graph shows the total number of publications written about "Biological Availability" by people in this website by year, and whether "Biological Availability" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Availability" by people in Profiles.
-
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Cancer Res. 2020 10 01; 80(19):4224-4232.
-
Transforming growth factor-?2 is sequestered in preterm human milk by chondroitin sulfate proteoglycans. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 01; 309(3):G171-80.
-
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014 Aug; 74(2):399-410.
-
1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as orally bioavailable transcriptional function suppressors of estrogen-related receptor a. J Med Chem. 2013 Jun 13; 56(11):4631-40.
-
Intestinal and hepatic first-pass extraction of the 11?-HSD1 inhibitor AMG 221 in rats with chronic vascular catheters. Xenobiotica. 2014 Mar; 44(3):264-9.
-
Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J Med Chem. 2012 Jun 14; 55(11):5291-310.
-
Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system? Reg Anesth Pain Med. 2010 Nov-Dec; 35(6):535-8.
-
Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem. 2009 Oct 22; 52(20):6474-83.
-
Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring). 2010 Mar; 18(3):604-10.
-
The clinical pharmacology of ethacrynic acid. Am J Ther. 2009 Jan-Feb; 16(1):86-92.